Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Emailed Dan

<< Previous

Bullboard Posts

Next >>

Post by Forestviewon Apr 05, 2021 1:32pm

513 Views

Post# 32937809

Emailed Dan

To see what is the timing on the ATE/AH amalgation completion. Based on the MC and SP, looks like there are 45.5 million ATE shares outstanding. I think after all is said and done we will be around 65 to 70million (that would include all the RSUs, bought deal, etc.).

I'll let the board know if I hear back.

<< Previous

Bullboard Posts

Next >>

Level up your trading with BMO InvestorLine’s enhanced features